Towards Healthcare

Pharmaceutical Stability & Storage Services Companies and Mergers and Acquisitions (M&A)

Date : 30 September 2025

Top Companies in the Pharmaceutical Stability & Storage Services Market

Pharmaceutical Stability & Storage Services Market Companies

  • Catalent, Inc.
  • Charles River Laboratories
  • Eurofins Scientific
  • Intertek Group plc
  • SGS SA
  • Labcorp Drug Development
  • PCI Pharma Services
  • Thermo Fisher Scientific (Patheon)
  • Almac Group
  • WuXi AppTec
  • Syngene International Ltd.
  • Piramal Pharma Solutions
  • Medpace Holdings, Inc.
  • IQVIA
  • BioStorage Technologies (Brooks Life Sciences)
  • Biocair International Ltd.
  • Nelson Labs (Sotera Health)
  • QPS Holdings
  • SGS Life Science Services
  • MicroConstants, Inc.

Market Growth

The global pharmaceutical stability & storage services market size is calculated at US$ 3.4 billion in 2024, grew to US$ 3.59 billion in 2025, and is projected to reach around US$ 5.92 billion by 2034. The market is expanding at a CAGR of 5.7% between 2025 and 2034.

The Make in India initiative is transforming India’s global pharmaceutical footprint. For instance, in April 2025, the Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, reported that India has remained the largest vaccine supplier of UNICEF for the past 6-7 years, which contributes 55% to 60% of the total volume procured. It has also been reported that India contributes 99%, 52% and 45% of the WHO demand for DPT, BCG, and measles vaccines.

The Government of India is driving cost-to-innovation-based growth by robust research activities. For instance, in July 2025, the Ministry of Chemicals and Fertilizers announced that the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme was launched with an expenditure of ₹ 5,000 crore to transform the Pharma MedTech sector of India.

Latest Announcements by Industry Leaders

In December 2024, Kasim Kutay, CEO of Novo Holdings, announced that the company feels delighted to invite Alessandro and the talented Catalent team to the Novo Holdings family. Catalent Inc. plays a significant role in accelerating product development, product launch, and supply solutions for pharmaceutical, biotechnology, and consumer health companies. He also reported that the company’s mission aligns with the goal of Novo Holdings to invest for the well-being of people and planet.

Recent Developments in the Pharmaceutical Stability & Storage Services Market

  • In January 2025, Catalent Inc. announced a collaboration with Galapagos for the expansion of Galapagos’ decentralized CAR-T manufacturing network in the U.S.
  • In April 2025, Thermo Fisher Scientific Inc. employed an enhanced platform technology and a new CHO K-1 cell line that can potentially reduce the period to Investigational New Drug (IND) filing from 13 to nine months, which will help biotechnology and pharmaceutical companies to resolve complexities in logistics within pre-clinical biologic drug development.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com